Sanofi and Alynylam rejig sees global rights switch-up
January 8, 2018Sales and Marketing Alynylam, Sanofi, biotech, drugs, pharma, pharmaceutical
The Sanofi-Alynylam alliance has been in place since 2014, with the latest development seeing the two companies each take their …
The PROs and cons of pushing patient centricity
January 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, patient reported outcomes, pharma
As the pharmaceutical industry places increasing weight on the importance of patient-reported outcomes in securing approvals, Ben Hargreaves examines how …
FDA clears Amgen’s bone drug for multiple myeloma
January 8, 2018Sales and Marketing Amgen, Cancer, Xgeva, multiple myeloma, pharma
Amgen has announced that the FDA has approved the indication expansion of its drug Xgeva (denosumab) to include the treatment …
Celgene in $7bn shot on Impact
January 8, 2018Sales and Marketing Celgene, Impact Biomedicines, biotech, drugs, pharma, pharmaceutical
Billions of dollars do not often get put down for drugs that have been dropped by a major pharma company, …
Novo Nordisk ups acquisition bid to €2.6 billion, Ablynx says no
January 8, 2018Sales and Marketing Ablynx, Novo Nordisk, acquisition, pharma
It has emerged that Novo Nordisk has extended a bid of €2.6 billion to buy Belgian biotech Ablynx. The new …
Pfizer exits neuroscience R&D space
January 8, 2018Research and Development, Sales and Marketing Pfizer, biotech, drugs, pharma, pharmaceutical
Pfizer announced over the weekend that it would be backing out of research and development into the neuroscience area, abandoning …
Philippines’ FDA suspends Dengvaxia marketing, Sanofi responds
January 5, 2018Medical Communications, Sales and Marketing Philippines, Sanofi, dengue, dengvaxia, pharma
As the Dengvaxia scandal in the Philippines rolls into 2018, it emerges that the country’s Food and Drugs Administration has …
Novartis Pharma Ex-CEO takes three roles in two days
January 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing David Epstein, Flagship Pioneering, biotech, drugs, pharma, pharmaceutical
Former CEO of Novartis Pharmaceuticals, David Epstein, has had a busy start to the year, accepting not one but three …
Top Ten most popular articles on Pharmafile.com this week
January 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten
Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …
Takeda agrees $630m takeover of TiGenix
January 5, 2018Medical Communications, Sales and Marketing Takeda, TiGenix, biotech, drugs, pharma, pharmaceutical
Takeda already had a strong working relationship with TiGenix, after previously signing a licensing agreement with the Belgium-based pharma company …
INC Research and inVentiv merge to form Syneos Health
January 4, 2018Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing INC Research, Syneos Health, inVentiv Health
With the advent of the new year, INC Research and inVentiv Health have announced they are to merge operations under …
Moderna Therapeutics names Dr John Medlein as new President, Corporate and Product Strategy
January 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Moderna, Moderna Therapeutics, mrna
Messenger RNA (mRNA) therapeutics and vaccines specialist Moderna Therapeutics has announced the appointment of current board member Dr John Medlein …
Common virus able to target brain cancer
January 4, 2018Medical Communications, Research and Development biotech, brain cancer, drugs, pharma, pharmaceutical
Research emerging from the University of Leeds and The Institute of Cancer research has revealed that a virus, known as …
NICE recommends first overseas treatment for use on NHS with GSK ‘bubble baby’ gene therapy
January 4, 2018Sales and Marketing ADA-SCID, GSK, GlaxoSmithKline, NHS, NICE, Strimvelis, bubble baby, pharma
NICE has chalked up a new first in its assessment of treatments for use on the NHS, ruling that the …
Pfizer makes $830m drug discovery pact with Arvinas
January 4, 2018Research and Development, Sales and Marketing Arvinas, Pfizer, biotech, drugs, pharma, pharmaceutical
Arvinas has managed to secure another big pharma collaboration, after it announced that Pfizer had signed a research and licensing …
New AI system for lung cancer and heart disease could save NHS billions
January 4, 2018Research and Development, Sales and Marketing Optellum, Oxford, Sir John Bell, heart disease, lung cancer, pharma
A team of researchers at Oxford’s John Radcliffe Hospital have unveiled a new artificial intelligence system which they claim could …
Allergan to axe over 1,000 positions in cost cutting measures
January 4, 2018Sales and Marketing Allergan, biotech, drugs, pharma, pharmaceutical
Allergan was never far away from the headlines in 2017, particularly when it came to its second highest selling product, …
Syntimmune brings in new CEO from Biogen
January 4, 2018Syntimmune, biotech, drugs, pharma, pharmaceutical
Syntimmune has revealed that it has brought in a new CEO to begin the new year, with the appointment of …
Spark’s bright idea on $850,000 blindness gene therapy
January 3, 2018Sales and Marketing : Pharma, Spark Therapeutics, biotech, drugs, pharma, pharmaceutical
Spark Therapeutics knew that it had to think very carefully about where it pitched its price for its inarguably ground-breaking …
J&J’s predicted blockbuster depression posts P2 data
January 3, 2018Research and Development Johnson & Johnson, biotech, depression, drugs, pharma, pharmaceutical
Johnson & Johnson has revealed Phase 2 data for its treatment for depression, esketamine, and the results are positive. The …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
